CALIFORNIA | LOCAL
April 24, 2012 |
George B. Rathmann, a far-sighted entrepreneur whose small team of talented scientists created two blockbuster drugs that helped turn his upstart Thousand Oaks firm, Amgen Inc., into the world's most successful biotech company, died Sundayat his Palo Alto home. He was 84. The cause was complications from pneumonia, according to his son, Richard. Biotechnology was still an embryonic business when Amgen opened in 1980. More than a quarter of a century after James Watson and Francis Crick had discovered DNA, the twisting molecular structure that carries life's genetic blueprint, the elaborate science of isolating key genes in the laboratory continued to elude researchers.
July 11, 2009 |
Biotechnology company Amgen Inc. said Rebecca Henderson had been appointed to its board of directors. Henderson, 48, recently became a professor at Harvard Business School. She has been a director at Idexx Laboratories Inc. since 2003. Her appointment expands the size of Thousand Oaks-based Amgen's board to 13.
June 13, 2002 |
Amgen Inc., the world's largest biotechnology company, said it would buy back as much as $2 billion of its stock, which has fallen 32% this year. The announcement, made after U.S. markets closed, sent shares of Thousand Oaks-based Amgen up 4.5% to $39.87 in heavy after-hours trading. The shares had closed off 58 cents at $38.17 on Nasdaq. Amgen has already repurchased about $1 billion of its own shares this year, and the board's authorization extends that, the company said.
March 29, 2000 |
Shares of Thousand Oaks-based Amgen Inc. rose 4%, gaining for a second day, as analysts said the world's No. 1 biotechnology company won an early round over rival Transkaryotic Therapies Inc. in a patent dispute involving Amgen's best-selling drug. U.S. District Judge William Young in Boston supported several Amgen claims during the last two days in a preliminary hearing over patents on Amgen's best-selling product, the $1.8-billion-a-year anemia treatment Epogen.
August 29, 2008 |
Amgen Inc. said it would stop offering rebates to cancer clinics prescribing its anemia drug Aranesp to avoid what it called the "possible misperception" that the payments encouraged overuse. The Thousand Oaks-based company also will change pricing for two other cancer drugs, Neulasta and Neupogen, by stopping discounts based on doctors' purchases of Aranesp and selling each product separately, Amgen said in a statement Thursday. Instead of rebates, Amgen will offer discounts at the time of purchase.
October 20, 2009 |
THOUSAND OAKS -- Amgen Inc. said today the Food and Drug Administration wants more information about its osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company. In a letter, the FDA said it wants to know how Amgen will monitor patients who use Prolia, and wants the company to develop a strategy to evaluate the risks of the drug, Amgen said. In premarket trading, Amgen shares fell $1.38, or 2.3 percent, to $59.94.